Skip to main content
SpringerLink
Log in

Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

This multicenter, double-masked, randomized, parallel-group study compared the efficacy and safety of ketorolac tromethamine 0.5% ophthalmic solution with levocabastine 0.05% and ketorolac tromethamine vehicle in patients with seasonal allergic conjunctivitis. One drop of ketorolac, levocabastine, or vehicle was instilled in each eye four times daily for 6 weeks. In the majority of efficacy variables, ketorolac produced the greatest improvements, followed by levocabastine and vehicle. Ketorolac was significantly more effective (P<.05) than vehicle in reducing mean itching scores, palpebral hyperemia, bulbar hyperemia, and edema. Patients treated with ketorolac reported significant improvements (P<.05) in their ability to sleep and to concentrate on work, compared with those who received vehicle. No significant differences were noted among the treatment groups in safety or tolerability. Ketorolac tromethamine 0.5% ophthalmic solution instilled four times daily is effective and safe in reducing the signs and symptoms of seasonal allergic conjunctivitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allansmith MR, Greiner JV, Baird RS. Number of inflammatory cells in the normal conjunctiva.Am J Ophthalmol. 1978;86:250–259.

    PubMed  CAS  Google Scholar 

  2. Capetola RJ, Rosenthale ME, Dubinsky B, McGuire JL. Peripheral analgesics.Clin Pharmacol. 1983;23:545–556.

    CAS  Google Scholar 

  3. Abelson MB, Butrus SI, Kliman GH, et al. Topical arachidonic acid: a model for screening anti-inflammatory agents.J Ocul Pharmacol. 1987;3:63–75.

    Article  PubMed  CAS  Google Scholar 

  4. Tinkelman DG, Rupp G, Kaufman H, Pugely J, Schultz N. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis.Surv Ophthalmol. 1993;38:133–140.

    Article  PubMed  Google Scholar 

  5. Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Ruff G. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis.Surv Ophthalmol. 1993;38:141–148.

    Article  PubMed  Google Scholar 

  6. Bahmer FA, Ruprecht KW. Safety and efficacy of topical levocabastine compared with oral terfenadine.Ann Allergy. 1994;72:429–434.

    PubMed  CAS  Google Scholar 

  7. Dawson JP. Comparative trial of 2% sodium cromoglycate unit-dose eye drops in seasonal allergic conjunctivitis. In: Pepys J, Edwards EM, eds.The Mast Cell. Its Role in Health and Disease. London: Pitman Medical; 1979:506–511.

    Google Scholar 

  8. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge—A clinical approach to studying allergic conjunctivitis.Arch Ophthalmol. 1990;108:84–88.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Connecticut Health Center, Farmington, Connecticut

    Peter C. Donshik M.D.

  2. Colorado Allergy & Asthma Clinic, Aurora, Colorado

    David Pearlman M.D.

  3. Allergy & Asthma Center of Arizona, Tucson, Arizona

    Jacob Pinnas M.D.

  4. New England Medical Center, Boston, Massachusetts

    Michael B. Raizman M.D.

  5. St. Luke’s Hospital, Leawood, Kansas

    Joseph Tauber M.D.

  6. National Jewish Medical and Research Center, Denver, Colorado

    David Tinkelman M.D.

  7. South Austin Medical Center, Austin, Texas

    Tom R. Walters M.D.

Authors
  1. Peter C. Donshik M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Pearlman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacob Pinnas M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael B. Raizman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joseph Tauber M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Tinkelman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tom R. Walters M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Donshik, P.C., Pearlman, D., Pinnas, J. et al. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis. Adv Therapy 17, 94–102 (2000). https://doi.org/10.1007/BF02854842

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02854842

Keywords

Search

Navigation